R

REGENXBIO Inc.

392 employees

REGENXBIO develops adeno-associated viral vector-based therapeutics and research tools, offering NAV, a recombinant AAV-vector.

Basic info

Industry

biotechnology research

Sectors

Biotechnology
Gene Therapy
Therapeutics
Genetics
Biopharma
Biopharmaceuticals

Date founded

2008

Funding rounds raised

Total raised

$71M

from 15 investors over 15 rounds

R

REGENXBIO Inc. raised undisclosed on January 1, 2020

Investors: Frazier Healthcare Partners

R

REGENXBIO Inc. raised $71M on May 20, 2015

Investors: Sectoral Asset Management, Jennison Associates LLC, RTW Investments, LP, QVT Financial LLP, Perceptive Advisors, F-Prime Capital Partners, Venrock and Vivo Capital

R

REGENXBIO Inc. raised $30M on January 21, 2015

Investors: Brookside Capital Inc, Venrock and F-Prime Capital Partners

R

REGENXBIO Inc. raised $7.7M on March 27, 2013

Investors: Fondazione Telethon and Executive Agency for Small and Medium-sized Enterprises (EASME)

R

REGENXBIO Inc. raised $2.8M on May 3, 2011

Investors: National Institutes of Health

FAQ